8-K: Xeris Biopharma Announces Board Changes: Fairley Resigns, Schmid Retires, Brady Appointed

Xeris Biopharma Holdings, Inc. announces the resignation of Ricki Fairley, the retirement of John Schmid, and the appointment of James Brady to its Board of Directors.

Summary

• Xeris Biopharma Holdings, Inc. announced changes to its Board of Directors effective March 28, 2025.
• Ricki Fairley resigned from the board due to other commitments.
• John Schmid will not stand for re-election at the 2025 Annual Stockholders Meeting, reducing the board size to eight members.
• James Brady has been appointed to the Board as a Class I director, with his term expiring at the 2025 Annual Meeting.
• Mr. Brady will also serve as Chair of the Board's Audit Committee, effective immediately following the 2025 Annual Meeting, subject to his reelection.
• Mr. Brady brings over 30 years of experience from AstraZeneca, including his role as Chief Financial Officer of MedImmune.
• He currently serves on the Board of Directors and as a Member of the Audit Committee of Verona Pharma plc (Nasdaq: VRNA).

Sentiment

Score: 7

Explanation: The announcement is neutral to positive. The addition of an experienced board member is generally viewed favorably, while the resignation and retirement are presented as amicable.

Positives

• James Brady's appointment brings extensive financial and operational experience from AstraZeneca and MedImmune to Xeris Biopharma's Board.
• Mr. Brady's experience includes successful national, regional and global finance roles in corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery and development.
• The company has granted Mr. Brady an initial equity grant of 100,000 restricted stock units, aligning his interests with shareholders.

Risks

• The press release contains forward-looking statements that are subject to various risks and uncertainties.
• These risks include the company's financial position, need for financing, market acceptance of products, reliance on third-party suppliers, and the ability to protect intellectual property.

Future Outlook

The company anticipates continued innovation and market presence expansion with the addition of James Brady to the Board.

Management Comments

• Marla Persky, Chairperson of the Board of Directors, stated that Jim is a seasoned and savvy business professional deeply steeped in the biopharmaceutical industry with broad-ranging public company financial expertise.
• Marla Persky also thanked John Schmid for his years of dedication to Xeris and excellent contributions to the Board, and Ricki Fairley for her marketing and patient community insights.

Industry Context

Board changes are common in publicly traded companies, reflecting evolving strategic priorities and the need for diverse expertise. The appointment of a seasoned executive like James Brady, with experience at AstraZeneca and MedImmune, suggests a focus on financial expertise and biologics development.

Comparison to Industry Standards

• James Brady's previous role as CFO of MedImmune, the biologics discovery and development division of AstraZeneca, is comparable to similar leadership positions at other major pharmaceutical companies such as Genentech (Roche) or Amgen.
• His experience in bringing five biologics to market during his tenure at MedImmune aligns with industry benchmarks for successful drug development and commercialization.
• His current board membership at Verona Pharma plc (Nasdaq: VRNA) is similar to other executives holding multiple board positions in the biopharmaceutical sector, such as those at companies like BioMarin or Vertex Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders may view the board changes positively due to the addition of an experienced executive.
• Employees may experience a change in leadership perspective with the new board member.
• The changes are not expected to have a direct impact on customers, suppliers, or creditors.

Next Steps

• James Brady will assume the role of Chair of the Audit Committee following the 2025 Annual Meeting, subject to his reelection.
• The Board size will be reduced to eight members after the 2025 Annual Stockholders Meeting.

Key Dates

Keywords

Board of Directors, James Brady, Ricki Fairley, John Schmid, Appointment, Resignation, Retirement, Corporate Governance, Xeris Biopharma, Director